About Argloyn Biosciences
Argolyn Bioscience is a biopharmaceutical company dedicated to discovering and developing peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. One of its development candidates is ABS201, a peptide derivative currently in preclinical development for the treatment of schizophrenia.
Missing: Argloyn Biosciences's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Argloyn Biosciences's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Argloyn Biosciences Frequently Asked Questions (FAQ)
Where is Argloyn Biosciences's headquarters?
Argloyn Biosciences's headquarters is located at Durham.
What is Argloyn Biosciences's latest funding round?
Argloyn Biosciences's latest funding round is Dead.
Who are the investors of Argloyn Biosciences?
Investors of Argloyn Biosciences include Quaker BioVentures.
Who are Argloyn Biosciences's competitors?
Competitors of Argloyn Biosciences include Apitope, BioMarck Pharmaceuticals, Raptor Pharmaceutical Corp., Motif BioSciences, Galenea and 11 more.
Compare Argloyn Biosciences to Competitors
Argolyn Bioscience is a privately held biopharmaceutical company dedicated to discovering and developing novel peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. Its most advanced development candidate is ABS201, a first-in-class peptide derivative currently in preclinical development for the treatment of schizophrenia.
Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.
BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Galenea is a biopharmaceutical company discovering and developing drugs to treat schizophrenia and other central nervous system diseases. The company has developed technology, the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, which enables direct high throughput screening of synaptic function in cultured primary neurons from mice and rats, and in neurons derived from human induced pluripotent stem cells. The company is using the MANTRA system to characterize synaptic dysfunctions in disease models and to identify signatures of therapeutic compound classes.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.